The compounds are orally active, selective and reversible inhibitors of monoamine oxidase-B (MAO-B). They have favourable preclinical profiles, and were well tolerated and showed excellent pharmacokinetic properties in phase I studies.
Under the terms of the agreement, Evotec will receive a worldwide exclusive license to two MAO-B compounds. In exchange, Roche will receive an upfront fee, and is eligible for milestone payments and royalties on net sales of products.
Roche retains a late stage co-development option on these compounds. In addition, upon initiation of phase II clinical trials, in lieu of a milestone payment, Roche will receive Evotec stock.
“We are encouraged by the potential of this compound as a disease modifier, which is the highest unmet medical need in Alzheimer’s disease. These drugs would be used in combination with, rather than in competition to, the currently available symptomatic treatments,” commented Jorn Aldag, president and CEO of Evotec.